Skip to main content
PEPTARA LABS
Get Started

Head to head

Retatrutide vs Tirzepatide: Trials Compared, 24% vs 22%

Published by · Updated · How we research and check our pages

Retatrutide vs tirzepatide is a side-by-side research comparison by Peptara Labs (peptaralabs.io) of two of the highest-efficacy GLP-1-class peptides in published trials: mechanism, clinical trial results and side effects. Retatrutide is a newer triple agonist that acts on GLP-1, GIP and glucagon receptors. Tirzepatide is the FDA-approved dual agonist that acts on GLP-1 and GIP. The 24% (Retatrutide Phase 2) and 22% (Tirzepatide Phase 3) figures come from separate trials with different durations and populations, not from a head-to-head study.

Verdict in 4 lines

  • Both are top-tier GLP-1 peptides.
  • Retatrutide is a newer triple-agonist with stronger Phase 2 weight-loss data (24.2%, 48 weeks).
  • Tirzepatide is the FDA-approved dual-agonist with the longest real-world track record (22.5%, 72 weeks).
  • Trial percentages cited below come from separate studies, not a head-to-head trial.

TL;DR comparison

One table, every row that matters. The weight-loss figures are each trial's highest dose group, from two separate trials rather than one head-to-head study.

Retatrutide
Tirzepatide
Class
GLP-1 / GIP / glucagon triple-agonist
GLP-1 / GIP dual-agonist
FDA status
Investigational (Phase 3 ongoing)
FDA-approved (Mounjaro, Zepbound)
Max trial weight loss
24.2% (Phase 2, 48 wk, highest dose group)
22.5% (Phase 3, 72 wk, highest dose group)
Trial reference
Jastreboff et al, NEJM 2023
SURMOUNT-1, NEJM 2022
Trial design
Phase 2, n=338, four dose levels vs placebo, 48 weeks
Phase 3, n=2,539, three dose groups vs placebo, 72 weeks

Mechanism: triple vs dual agonist

Both peptides work by activating gut and pancreatic hormone receptors that regulate appetite, insulin secretion, and energy expenditure. The difference is how many of those receptors each one activates.

Tirzepatide (dual-agonist)

Activates two receptors: GLP-1 (glucagon-like peptide 1, slows gastric emptying and suppresses appetite) and GIP (glucose-dependent insulinotropic peptide, boosts insulin sensitivity and may modulate fat storage). The dual activation produces stronger fat loss than older single-agonist GLP-1 drugs like semaglutide.

Retatrutide (triple-agonist)

Activates all three: GLP-1, GIP, and glucagon receptor. The glucagon-receptor arm adds direct energy expenditure (the body burns more calories at rest), on top of the appetite suppression and insulin effects of GLP-1 and GIP. That third pathway is the main reason Phase 2 fat-loss numbers exceeded Tirzepatide.

Honest trade-off: more receptor activation means more potential side effects. The triple-agonist mechanism that drives Retatrutide's stronger fat-loss percentage also produced higher rates of GI events in the highest dose group of the phase 2 trial (Jastreboff et al., 2023).

Clinical trial results

The headline figures, the trial citations, and the disclaimer that has to come with them.

Retatrutide Phase 2

  • Reference: Jastreboff et al, NEJM 2023
  • Phase: 2
  • n: 338
  • Duration: 48 weeks
  • Cohort: highest dose group
  • Result: 24.2% mean body weight reduction

Tirzepatide Phase 3 (SURMOUNT-1)

  • Reference: SURMOUNT-1, NEJM 2022
  • Phase: 3
  • n: 2,539
  • Duration: 72 weeks
  • Cohort: highest dose group
  • Result: 22.5% mean body weight reduction

Read this before quoting either number

These percentages come from two separate clinical trials with different durations (48 vs 72 weeks), different patient populations, and different trial phases (2 vs 3). A direct percentage comparison should be read as descriptive, not causal. A head-to-head trial of Retatrutide vs Tirzepatide has not been published as of 2026. The Peptara position: cite the numbers honestly, name the trials, and never imply a direct A-beats-B finding the literature has not yet produced.

Side effects

Both share the GLP-1 class profile. Each has compound-specific notes worth flagging.

Shared (GLP-1 class)

  • Nausea
  • Vomiting
  • Constipation
  • Decreased appetite
  • Fatigue

Retatrutide-specific

  • Higher GI rate in the highest dose group than in lower dose groups (Phase 2)
  • Triple-agonist activation can amplify nausea
  • Investigational compound: longer-term safety data still accumulating

Tirzepatide-specific

  • FDA black-box warning: thyroid C-cell tumors (rodent data)
  • Rare reports of pancreatitis
  • Gallbladder events (cholelithiasis, cholecystitis)

In both trials, gastrointestinal effects were mostly mild to moderate (Jastreboff et al., 2022; Jastreboff et al., 2023).

Frequently asked questions

Is Retatrutide better than Tirzepatide?

Retatrutide produced a higher mean body weight reduction in its Phase 2 trial (24.2% at 48 weeks, highest dose group) than Tirzepatide did in SURMOUNT-1 (22.5% at 72 weeks, highest dose group). But these are separate trials, not a head-to-head comparison. Different durations, different populations, different phases. Retatrutide is mechanistically a triple-agonist (GLP-1, GIP, glucagon) and tends to drive stronger fat loss in trials. Tirzepatide is dual-agonist and FDA-approved with years of real-world data. Which looks stronger depends on the measure: the larger trial percentage (retatrutide) or the regulatory track record (tirzepatide).

Which has fewer side effects?

Both peptides share the GLP-1 class side-effect profile reported in trials: nausea, vomiting, constipation and decreased appetite. In the retatrutide phase 2 trial, gastrointestinal events were the most common adverse events and were dose-related (Jastreboff et al., 2023). Tirzepatide carries an FDA black-box warning for thyroid C-cell tumors (rodent data, no confirmed human signal) and has rare reports of pancreatitis and gallbladder events. In both trials, gastrointestinal effects were mostly mild to moderate (Jastreboff et al., 2022; Jastreboff et al., 2023).

Why are these two compared so often?

They are two of the highest-efficacy GLP-1-class peptides in published trials. Tirzepatide is the FDA-approved benchmark for weight loss. Retatrutide is the most-anticipated next-generation candidate, which is why "Retatrutide vs Tirzepatide" is the single highest-volume comparison query in the space.

Is Retatrutide FDA-approved?

No. As of 2026, Retatrutide is investigational. Phase 3 trials are ongoing under Eli Lilly. Tirzepatide is FDA-approved under the brand names Mounjaro (Type 2 diabetes) and Zepbound (weight loss).

Are these trial numbers from the same study?

No. The 24.2% Retatrutide figure comes from Jastreboff et al, NEJM 2023, a Phase 2 trial, n=338, 48 weeks, highest dose group. The 22.5% Tirzepatide figure comes from SURMOUNT-1, NEJM 2022, a Phase 3 trial, n=2539, 72 weeks, highest dose group. These are separate trials with different durations, different patient populations, and different trial phases. A direct percentage comparison should be read as descriptive, not causal. As of 2026 no head-to-head trial of Retatrutide vs Tirzepatide has been published.

Questions about how these two trials were set up?

This page lays out the trial designs and approval records side by side. Peptara Labs works with research compounds for laboratory use only. Send us a WhatsApp message and someone real will reply.

Ask on WhatsApp
Chat with us